Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

Shares of Hikma Pharmaceuticals PLC HIK slipped 2.64% to £17.72 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 0.07% ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma ... business and are pleased to announce the signing of a significant new long-term contract with a global pharmaceutical company. Subject to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Out-of-home posters using the term “HER2.0” showed that the drug could also be used to fight gastrointestinal cancers.

Telix Pharmaceuticals Ltd. (AU:TLX) has released an update. Telix Pharmaceuticals Ltd. is set to benefit from a new CMS policy that ensures separate payments for specialized diagnostic ...

made by Hikma Pharmaceuticals, did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement ...

Acumen Pharmaceuticals has been making significant strides in its clinical trials and financial status. The biopharmaceutical firm recently presented new data from its Phase 2 ALTITUDE-AD clinical ...

Clarity Pharmaceuticals Ltd. has announced the issuance of 16,677 new options set to expire on October 1, 2029, with an exercise price of $9.424, as part of an employee incentive scheme.